ATTENTION HAVE YOU HAD THE CHICKEN POX? HEALTH CARE PROFESSIONALS: Chicken Pox & Childbearing
|
|
- Scott Glenn
- 6 years ago
- Views:
Transcription
1 Chicken Pox & Childbearing ATTENTION HEALTH CARE PROFESSIONALS: HAVE YOU HAD THE CHICKEN POX? H ere s one scenario worth exploring: a neonatal intensive care unit nurse receives a telephone call from a friend, who informs her that he has just come down with the chicken pox. She went to the movies with him just two days before, but hadn t seen him since the outbreak. To the best of her knowledge, she hadn t ever had the chicken pox. How can she find out if she possesses an immunity to the virus? And if she s not immune, when is it safe for her to return to work with the newborns? After an immunoglobulin G (IgG) latex agglutinate test to check her immunity, it was determined that the nurse didn t possess the antibodies to the varicella virus; therefore, she was seronegative. Because the nurse s friend was contagious for five days before his outbreak or until the vesicles had granulated over, she may have been exposed to the virus and should have been considered potentially infectious for the 10th through the 21st day after exposure. Because the nurse was exposed two days ago, she can safely work with newborns for the next eight days, but shouldn t work in a clinical setting for the following 11 days. The nurse could be offered varicella zoster immune globulin (VZIG). If she has an outbreak of the chicken pox, the nurse needs to avoid the clinical setting until all of the lesions have formed scabs. If the nurse doesn t break out during those 11 days, she needs to receive her first varicella vaccination and her second vaccination four to eight weeks later. During this time and for six weeks after the last vaccination, she should not work with newborns or any other patients who may be immunocompromised because of the slight risk of infecting them with the virus. Emiromnental Pemptive Between 5 to 15 percent of adults in the US. don t have immunity to varicella, the virus that causes the chicken pox. The varicella vaccine can significantly reduce the incidence of varicella infections in pregnancy and should be given before women are of childbearing age. Susceptible health care workers can help prevent transmission of VZV by being vaccinated. However, it s not clear how long protection lasts after vaccination. Studies Barbera Hansen Cottrell, ARNP, MSN Carrie C. Carter August 1998 AWHONN Lifelines 33
2 are ongoing to evaluate the need and timing for booster vaccination. The 1995 development of a vaccine to prevent varicella resulted in new recommendations for health care workers. The first recommendations by the Advisory Committee on Immunization Practices (ACIP) were published in July, Both the Hospital Infection Control Practices Advisory Committee and the ACIP recommended that all susceptible health care workers ensure that they are immune to varicella, and serologic screening of all health care workers with a negative or uncertain history of varicella was recommended to document immunity (CDC, 1996). These recommendations are particularly important for those working with pregnant women and newborns. Although these recommendations have been available for more than two years, there are still susceptible health care workers who haven't been immunized. Because of the profound effects of gestational varicella, the importance of susceptible health care workers being immunized can't be overemphasized. Health care workers who don't know if they're immune can easily test for immunity. The availability of the varicella vaccine also opened new options for preventing chicken pox in pregnancy. Health care professionals should be asking all women of childbearing age whether they've had the chicken pox, particularly during preconception counseling. For those who aren't sure whether they've had chicken pox, serologic testing or vaccination should be offered if there are no contraindications. For those who have had varicella, there's at least a 97 percent chance that they're immune (Stevenson, 1996). Pregnant women shouldn't receive the vaccine, and pregnancy should be avoided for three months after receiving the vaccine (Merck, 1997). looking at Varicella Varicella is highly contagious and is caused by the DNA varicella zoster virus (VZV). The varicella virus most often manifests as seasonal epidemics, typically in late winter and early spring. Although more than six million doses of vaccine have been administered since licensure of the live attenuated varicella vaccine, there are still millions of cases annually in the U.S. In fact, 10 percent of all varicella cases occur in people 15 years old or older, and as many as 500,000 individuals seek medical care for their symptoms. Approximately 125 deaths occur annually in the U.S. with varicella as an underlying cause (Wharton, 1996). For a normal, healthy child, the mortality rate is less than two per 100,000 and is usually caused by septic complications and encephalitis (Beneson, 1995). For adults, that rate increases more than 15 fold (Whitley, 1995) and mortality risk is due to primary viral pneumonia (Beneson, 1995). Varicella also occurs in as many as five per 10,000 pregnancies (Mclntosh & Isaacs, 1993). VZV is a human herpes virus. The primary infection, Barbara Hansen Cottrell, ARNP, MSN, is an associate professor at Florida State University in Tallahassee, FL. Carrie C. Carter is an undergraduate nursing student at Florida State University. Testing for Immunity A positive history of varicella is 97 percent predictive of a serologic immunity (CDC, 1996). Serologic tests are available for IgG antibodies to VZV. Tests differ in their ability to detect antibody acquired from natural varicella versus antibody acquired from vaccination. Single serologic IgG tests are used to identify the immune status of persons with a negative or uncertain history of varicella who may be candidates for VZlG or vaccination. Factors in selecting an antibody-detection assay include test sensitivity and specificity, the length of time required to obtain results, and availability of the assay (CDC, 1996). The following tests may be ordered (Seward et al., 1997): Enzyme-linked immunosorbent assays (ELISA) Fluorescent antibody to membrane antigen (FAMA) Latex agglutination (LA) lndirect hernagglutination (IHA) Immune adherence hemagglutination (IAHA) Complement fixation (CF) The LA test can be completed in 15 minutes but is less sensitive in detecting the antibody after vaccination, though still more sensitive than commercial ELlSAs (CDC, 1996). The FAMA test is considered the "gold standard" for screening for immune status for VZV, but isn't widely available. varicella, results from exposure of a susceptible individual to the virus. Symptoms include a generalized vesicular rash, low-grade fever, and malaise. A prodrome of symptoms may occur one to two days before breakout. The skin manifestations are the hallmark of chicken pox. They appear as maculopapules, vesicles, and scabs in varying stages of evolution. The lesions initially contain clear vesicular fluid, but quickly pustulate and scab. The first of the lesions appear on the trunk and face and rapidly spread centripetally to involve other areas, and may include the oral mucosa and vagina (Whitley, 1995). Successive crops of lesions appear over a period of two to four days. The scabs fall off within one to two weeks and leave a slightly depressed area of the skin. The healing process can take up to three times longer for immunocompromised persons. Serious complications, like encephalitis and pneumonia, rarely occur. After varicella, VZV persists in a latent form in sensory-nerve ganglia without any symptoms. The latent virus is reactivated in approximately 15 percent of people, who subsequently develop herpes zoster, or "shingles. How Varicella Spreads The varicella virus can be transmitted person-to-person through direct contact, airborne spread of vesicle fluid, or by secretions of the respiratory tract. Congenital infections may also occur. Indirectly, varicella can be transmitted through articles freshly soiled by discharge 34 AWHONN Lifelines Volume 2, Issue 4
3 Precautions After Vaccination 1. Epinephrine injection (1:lOOO) should be available for immediate use if an anaphylactic reaction should occur 2. Pregnancy should be avoided for 1 month after each dose of the vaccine (AAP, 1997). Because two doses of the vaccine are given four to eight weeks apart, the CDC recommends avoiding pregnancy for three months after the initial vaccination. The manufacturer has strengthened that recommendation and has indicated that pregnancy should be avoided for three months after the completion of vaccination (Merck, 1997). 3. Although rare, persons who have been given Varivax are potentially capable of transmitting the vaccine strain of virus to susceptible close contacts. Secondary transmission from the vaccine virus may be possible as early as five days postexposure (Seward et al., Therefore, recipients should avoid association with persons with weakened immune systems for six weeks after vaccination. A mild varicellalike rash has been observed in approximately 7 percent of vaccinees, and those with the rash are considered contagious (Merck, 1997). 4. Vaccine recipients should avoid the use of salicyclates for six weeks after vaccination with varicella, because Reye's syndrome has been reported after the use of salicyclates during natural varicella infections (AAP, 1997). from vesicles and mucus membranes of infected people. The scabs from varicella lesions are not infective. The vesicle fluid of patients with herpes zoster can also transmit chicken pox, but this transmission rate is low (Beneson, 1995). Because of the ease of transmission, airborne and contact precautions are necessary. Clients hospitalized with VZV and susceptible patients who have been exposed to the virus should be isolated, preferably in a single room with negative air-pressure ventilation with externally exhausted or high-efficiency particulate air filters if the air is recirculated (American Academy of Pediatrics [AAP], 1977). Masks, gowns, and gloves should be worn. Susceptible personnel who were exposed should be furloughed away from patient care areas and screened daily for skin lesions, fever, and systemic symptoms (CDC, 1996). Only personnel who are immune to varicella should care for patients with VZV. VZV incubates from two to three weeks, and an individual is considered contagious for five days before the appearance of the first lesions until five days after the appearance of the last lesions. Exposed susceptible individuals should be considered infectious for 10 to 21 days after exposure (CDC, 1996). The incubation period may be prolonged for as long as 28 days when varicellazoster immune globulin (VZIG) is given (AAP, 1997). Pox in Pregnancy Chicken pox during pregnancy (gestational varicella) is rare, but can be dangerous for the fetus, mother, and newborn. Varicella in pregnant women is associated with a risk for VZV transmission to the fetus with resulting multiple system damage, clinical varicella in the newborn, or clinical herpes zoster during infancy and early childhood (CDC, 1996). The incidence of premature birth is substantially increased among women with chicken pox (Katz et al., 1995). The fetus of a woman with gestational varicella has a 2 to 3 percent chance of developing varicella embryopathy (Grant, 1996), also known as congenital varicella syndrome (CDC, 1996). Manifestations of this include skin scaring, intrauterine growth retardation, limb hypoplasia and other skeletal lesions, and central nervous system involvement. Cataracts, chorioretinitis, deafness, and microcephaly may result (Katz et al., 1995). The low risk of developing varicella embryopathy suggests a limited ability for the virus to cross the placenta and infect the fetus. Fetal risks are usually limited to fetal exposure before 20 weeks gestation (Katz et al., 1995), but embryopathy has been reported from infection as late as 26 weeks (Jones et al., 1994). Recommended treatment for gestational varicella depends on the number of weeks gestation and the mother's health status. An otherwise healthy woman with mild symptoms should be first treated symptomatically with fluids, antipyretics, and antipruritics. If she is near term, it's best to delay delivery for five to seven days to allow maternal antibodies to develop and transfer to the fetus (Paulman & McLellan, 1990). Pregnant women who are susceptible and exposed to varicella should strongly consider getting VZIG after exposure (CDC, 1996). VZIG is prepared from the plasma of blood donors with a high antibody titer to VZV. Immune globulin may not eliminate the incidence of varicella embryopathy, but, if given before maternal infection develops, it may increase or attenuate fetal disease (Enders et al., 1994). If the woman has a varicella infection and delivers within five days, or has the virus within 48 hours after delivery, VZIG is indicated. It's effective in modifying or preventing further manifestations of the disease if given within 96 hours after exposure to VZV. Typically, VZIG is available from blood centers and costs between $600 and $800 per dose. Because VZIG is considered preventive, it may not be covered by insurance (Grant, Exploring the Vaccine The vaccine is a live, attenuated varicella virus. It must be stored frozen at an average temperature 25 F (15 C). The diluent should be stored separately either at room temperature or in the refrigerator. The vaccine should be reconstituted according to the manufacturer's directions and only the diluent supplied because the diluent supplied doesn't contain preservatives or other antiviral substances that could inactivate the vaccine. The vaccine should be used within 30 minutes after reconstitution or discarded (CDC, 1996). August 1998 AWHONN Lifelines 35
4 I Dealing With Susceptible Health Care Workers Susceptible health care staff who are not VZV immune and are exposed to varicella should be furloughed or excused from patient contact from day 10 to day 21 after exposure. If the staff member is pregnant and healthy, VZlG should be given. VZlG can be given to healthy, susceptible adults after exposure to varicella, but isn t routinely recommended if the patients are pregnant (AAP, 1997). The administration of VZIG can prolong the average incubation period, so recipients should be furloughed away from patient contact for 10 to 28 days after exposure (CDC, 1996). After this time period, varicella vaccine is recommended for all susceptible staff if varicella doesn t develop. For those in whom varicella does develop, Acylovir should be considered for otherwise healthy health care workers. Acylovir should be given within 24 hours of the onset of the rash to decrease the magnitude and duration of fever and the number and duration of skin lesions. 1996). Protection with VZIG against varicella lasts only about three weeks. If the pregnant woman has a severe case of varicella, marked by a rapid, extensive rash, high fever, and pulmonary involvement, antiviral therapy may be considered during the third trimester. The incidence of varicella pneumonia is highest in the third trimester (approximately 13 percent) with an estimated mortality rate of 40 percent (Katz et al., 1995). Acylovir is the drug of choice for these pregnant women in their third trimester. Acylovir is classified as a Category C by the FDA (because risk can t be ruled out, but potential benefits may justify the possible risk) and is not recommended routinely in pregnant adolescents or adults with uncomplicated varicella because the risks and benefits to the fetus and mother are unknown (AAP, 1997). Controlled studies among pregnant women who have been given Acylovir haven t been conducted (CDC, 1996). Newborns & Chicken Pox Varicella can develop between one and 16 days after birth in infants born to mothers with acute varicella. The interval between the onset of rash in the mother to the onset in the neonate is nine to 15 days (AAP, 1997). Newborns with varicella should be allowed to breastfeed, be isolated with the mother, and should be discharged as soon as possible (Lawrence, 1994). Newborns of women who experience the onset of varicella from five days before to two days after delivery have a 17 to 30 percent chance of severe varicella infection because they don t have sufficient maternal antibody to lessen the severity of disease. For this reason, the AAP (1997) recommends that these infants be given VZIG 125 units as soon as possible after birth. These newborns have up to a 30 percent risk for death if their mothers had onset of rash one to four days before giving birth unless VZIG is given (CDC, 1996). Varicella can be expected to develop in approximately half of the infants given VZIG, but the disease is often modified and much less severe. VZIG recipients should be observed closely. For healthy, full-term newborns exposed postnatally to varicella, including those whose mother s rash developed more than 48 hours after delivery, the AAP (1997) states that VZIG isn t indicated. The newborn of a woman who contracted gestational varicella within three weeks before delivery has a 25 percent chance of being born with a rash. Infants with active varicella should be kept away from other infants and preferably isolated with their mothers (CDC, 1996). Both airborne and contact precautions are recommended for newborns with varicella as long as the rash remains vesicular. Airborne and contact precautions are recommended also for neonates born to women with varicella and, if hospitalized, continued until 21 days or 28 days after VZIG was given. Infants born with varicella embryopathy don t require isolation (AAP, 1997). Premature Infants Premature infants of less than 28 weeks gestation or infants whose mother had onset of chicken pox from five days before to 48 hours after delivery should receive VZIG. Also, VZIG is indicated for infants born before 28 weeks gestation (or who weigh less than 1,000 g) who still require hospitalization for treatment of prematurity or related conditions and are exposed to varicella or zoster. Preterm infants born after 29 weeks of gestation who are exposed in the hospital and whose mothers have no history of infection andlor are seronegative should also be given VZIG (AAP, 1997). Breastfeeding VZV hasn t been found in breast milk in women with varicella (Frederick et al., 1996). Breast milk has tested positive for varicella-zoster DNA in one study (Yoshida et al., 1992), but it s possible that the milk may have been contaminated through direct contact with skin lesions or airborne droplets. Mothers with varicella can maintain lactation with a pump, discarding pumped milk until they are no longer infectious. If a woman decides to breastfeed, the infant should be protected from direct contact with mom s skin rash and the mother should wear a mask. Antibodies appear in milk within 48 hours of the disease onset (Lawrence, 1994). It s not known if the attenuated vaccine is excreted in human milk, and whether the infant could be infected during breastfeeding. For this reason, the vaccine manufacturer recommends that nursing mothers not receive the vaccine (Merck, 1997). The CDC (1996) states the varicella virus vaccine may be considered for a nursing mother. If the risk of exposure to natural VZV is high, the vaccine may be considered (AAP, 1997). Guidelines for Vaccination Nonpregnant Women of Childbearing Age Vaccination of women who aren t pregnant but may become pregnant in the future will reduce the risk for 88 AWHONN Lifelines Volume 2, Issue 4
5 Reporting Inadvertent Vaccination Inadvertent vaccination of pregnant women with the varicella vaccine should be reported. The manufacturer, in collaboration with the CDC, has established the VARIVAX Pregnancy Registry to monitor the maternal-fetal outcomes of pregnant women who are inadvertently administered the varicella virus three months before or during pregnancy. Health care professionals can call (800) to register their patients. Because the virulence of the attenuated virus used in the vaccine is less than that of the wild-type virus, and because the wild-type virus poses a very small risk to the fetus, the decision to terminate a pregnancy shouldn t be based on whether the vaccine was administered during pregnancy. VZV transmission to the fetus. Women should first be asked if there is any possibility that they may be pregnant and advised to avoid pregnancy for three months after the first dose of the vaccine (CDC, 1996). The drug manufacturer (Merck, West Point, PA) is more cautious; they recommending that women avoid pregnancy for three months after completion of the vaccination. Inadvertent administration of varicella vaccine should be reported. Children The vaccine is recommended for all susceptible children ages 1 year and older before their 13th birthday. Persons younger than 13 years of age should receive 0.5 ml doses of the vaccine subcutaneously. Persons ages 13 and older should receive a 0.5 ml dose on a selected date and a second 0.5 ml dose four to eight weeks later. Results from clinical studies indicate that varicella vaccine can be administered concomitantly with MMR I1 drawn up in separate syringes using separate injection sites (Facts and Comparisons Publishing Group, 1998). If not given on the same day as the MMR vaccine, the interval between the varicella vaccine and MMR should be at least one month (AAP, 1997). A pregnant mother or other member of the household is not a contraindication for vaccination of the child, because more than 90 percent of adults are immune. Although rare, the varicella vaccine virus has been transmitted by a healthy vaccinee to contacts with only mild or symptomatic infection reported (AAP, 1997). However, if the pregnant woman is known to be susceptible, some experts recommend deferring immunization of the child until the third trimester or until after delivery, if feasible (AAP, 1997). Health Care Workers Health care workers who have never had varicella should be immunized with two 0.5 ml doses of vaccine subcutaneously, four to eight weeks apart (CDC, 1996). The outer aspect of the upper arm is the preferred site of injection. Approximately 90 percent of adults seroconvert after two doses and can be expected to be protected against varicella. About 70 percent will be completely protected; the remaining 30 percent will develop modified varicella with an average of 50 skin lesions and rapid recovery (Donowin, 1996). These people should avoid contact with susceptible high-risk persons such as newborns and pregnant women for as long as the rash remains vesicular (Facts and Comparisons, 1998). Approximately 10 percent of those who are immunized and subsequently seroconvert lose detectable antibodies within several years after varicella; those that do are among the 30 percent who are at risk for breakthrough varicella (Donowitz, 1996). If no seroconversion occurs after two doses, a third dose may be given. Seroconversion is often measured by the latex agglutination assay for VZV antibodies and can help in the management of personnel assigned to high-risk areas, such as obstetric areas and newborn nurseries. Contraindications Pregnant women shouldn t be vaccinated because the effects of the varicella virus vaccine on the fetus are unknown (CDC, 1996). Patients who shouldn t be given the varicella vaccine are those who have (Brody& Moyer, 1997; Facts and Comparisons, 1998; Zimmerman, 1996): Leukemia 0 Lymphoma Blood dyscrasia or any other malignant neoplasms affecting the bone marrow or lymphatic systems Immunosuppressive therapy or immunodeficiency A family history of congenital or hereditary immunodeficiency HIV infection Febrile illness (>lol F) Active, untreated tuberculosis A history of hypersensitivity to any vaccine component such as gelatin or anaphylactoid reaction to neomycin Hypogammaglobulinemic and dysgammaglobulinemic states A blood transfusion within the past five months Immune globulin or VZIG within the preceding five months It s not known if the administration of immune globulin can interfere with the immunologic response to varicella vaccination. Immune globulin administration can interfere with the response to other live-virus vaccines. Because of the potential inhibition of the response to varicella vaccination by passively transferred antibodies, varicella vaccine shouldn t be given for at least five months after the administration of immune globulins, VZIG, blood products (excluding red blood cells), or plasma transfusions (AAF, 1997). If an immune globulin is given within five months before vaccination (as in a Rh-negative mother with a Rh-positive infant), the recipient either should be revaccinated five months later or tested for varicella immunity six months later and revaccinated if seronegative (AAP, 1997). + References Adkins, S. B. (1997). Immunizations: Current recommendations. American Family Physician, 56, 865. August 1998 AWHONN Lifelines 37
6 Acylovir Data Being Collected Data are currently being collected by the Centers for Disease Control and Prevention along with Burroughs Wellcome Company on the fetal-maternal outcomes of pregnant women given Acylovir. All health care providers are encouraged to register pregnant women treated with Acylovir by calling (800) American Academy of Pediatrics. (1997). Red book: Report of the Committee on Infectious Diseases. (24th Ed.). Elk Grove Village, IL: American Academy of Pediatrics. Beneson, A. S. (1995). Control of communicable diseases manual. Washington, DC: American Public Health Association. Brody, M. B., & Moyer, D. Varicella-zoster virus infection. Postgraduate Medicine, Temple University Series, 102, 187. Centers for Disease Control and Prevention (1996). Prevention of varicella: Recommendations of the Advisory Committee on Immunizations (ACIP). Morbidity and Mortality Weekly Report, 45, Donowitz, L.G. (1996). Infection control in the child care center and preschool. (3rd Ed.). Baltimore: Williams & Wilkins. Enders, G., Miller, E., Cradock-Watson, J., Bolley, I., & Ridehalgh, M. (1994). Consequences of varicella and herpes zoster in pregnancy: prospective study of 1,739 cases. Lancet, 343, Facts and Comparisons Publishing Group. (1998) drug facts and comparisons pocket book (2nd Ed.). St. Louis: Facts and Comparisons. Frederick, I. B., White, R. J., Braddock, S. W. (1986). Excretion of varicella herpes zoster in breast milk. American Journal of Obstetrics and Gynecology, 154, Grant, A. (1996). Varicella infection and toxoplasmosis in pregnancy. Journal of Perinatal and Neonatal Nursing, 2(10), Jones, K.L., Johnson, K.A., & Chambers, C.D. (1994). Offspring of women infected with varicella during pregnancy: A prospective study. Teratology, 49, Katz, V.L., Kuller, J.A., McMahon, M.J., Warren, M.A. & Wells, S.R. (1995). Varicella during pregnancy: Maternal and fetal effects. Western Journal of Medicine, 163, Lawrence, R.A. (1994). Breastfeeding: A guide for the medical profession (4th ed.) St. Louis: Mosby. McIntosh, D. & Isaacs, D. (1993). Varicella zoster virus infection in pregnancy. Archives of Disease in Childhood, 68, 1-2. Merck & Co. (1997). Varivax product information. West Point, PA: Merck & Co., Circular No Paulman, P., & McLellan, R. (1990). Varicella during pregnancy: The timing of effective treatment. Journal of the American Board of Family Practice, 2, Seward, J., Reef, S., Meyer, P., Kilgore, P., & Wharton, M. (1997). Varicella. [Online] Available: ( 1997, September 12). Wharton, M. (1996). The epidemiology of varicella-zoster virus infections. Infectious Disease Clinics of North America, 10, Whitley, R. J. (1995) Varicella-zoster virus. In G. L. Mandell, J. E. Bennett, & R. Dolins (Eds.) Principles and practice of infectious diseases (4th Ed). (pp ). New York: Churchill Livingstone. Yoshida, M., Yamagami, N., Tezuka, T., & Hondo, R. (1992). Case report. Detection of varicella virus DNA in maternal breast milk. Journal of Medical Virology, 38, Zimmerman, R.K. (1996). Varicella vaccine: Rationale and indications for use. American Family Physician, 53,
To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More informationIMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine
IMMUNIZATION PROTOCOLS FOR PHARMACISTS VARICELLA Live Virus Vaccine I. ORDER: 1. Screen for contraindications and evidence of immunity (Section VII.K.) 2. Provide a current Vaccine Information Statement
More informationProf Dr Najlaa Fawzi
1 Prof Dr Najlaa Fawzi is an acute highly infectious disease, characterized by vesicular rash, mild fever and mild constitutional symptoms. is a local manifestation of reactivation of latent varicella
More informationVaricella (Chickenpox) and Varicella Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Varicella (Chickenpox) and Varicella Vaccines September 2018 Photographs and images included in this
More informationMeasles, Mumps and Rubella. Ch 10, 11 & 12
Measles, Mumps and Rubella Ch 10, 11 & 12 Measles Highly contagious viral illness First described in 7th century Near universal infection of childhood in prevaccination era Remains the leading cause of
More informationA summary of guidance related to viral rash in pregnancy
A summary of guidance related to viral rash in pregnancy Wednesday 12 th July 2017 Dr Rukhsana Hussain Introduction Viral exanthema can cause rash in pregnant women and should be considered even in countries
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationHealth Care Worker (Pregnant) - Infectious Diseases Risks and Exposure
1. Purpose The purpose of this guideline is to provide accurate information on the risks to pregnant Health Care Workers (HCWs) in the event of an exposure to a transmissible infectious disease at the
More informationAtlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique
Atlantic Provinces Pediatric Hematology Oncology Network Réseau d oncologie et d hématologie pédiatrique des provinces de l Atlantique Reviewed and approved by specialists at the IWK Health Centre, Halifax,
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Chickenpox Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Caused
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Chickenpox Caused
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationVaricella and varicella vaccination An update
THEME: School contagions Varicella and varicella vaccination An update John Litt, Margaret Burgess BACKGROUND Although varicella is generally mild in children, it is often more severe in adults and overall
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationEXANTHEMATOUS ILLNESS. IAP UG Teaching slides
EXANTHEMATOUS ILLNESS 1 DEFINITIONS Exanthema eruption of the skin Exanthema eruption of mucosae Macule flat nonpalpable lesion Papule small palpable lesion Nodule large palpable lesion Vesicle small fluid
More informationChickenpox Notification
Goolwa Campus: (08) 8555 7500 Victor Harbor Campus: (08) 8551 0900 Investigator College Chickenpox Notification Date for Distribution: 2018 Dear Parents/Caregivers There has been a case of chickenpox reported
More informationSTANDARD OPERATING PROCEDURE (SOP) CHICKENPOX [VARICELLA ZOSTER VIRUS (VZV)]
Page 1 of 9 SOP Objective To ensure that patients with chickenpox (Varicella Zoster Virus) are cared for appropriately and actions are taken to minimise the risk of cross-infection. This SOP applies to
More informationCounty of Santa Cruz. General Questions About Measles HEALTH SERVICES AGENCY. Public Health Division. What is measles?
County of Santa Cruz Public Health Division HEALTH SERVICES AGENCY POST OFFICE BOX 962, 1080 EMELINE AVE., SANTA CRUZ, CA 95060 TELEPHONE: (831) 454-4000 FAX: (831) 454-4770 General Questions About Measles
More informationLECTURE OUTLINE. B. AGENT: Varicella-zoster virus. Human herpes virus 3. DNA virus.
Viral Vaccines II LECTURE OUTLINE 5/24/04 I. CASE HISTORY A 5-year old comes home from school with a red skin rash on his chest that spreads to over 300 itchy blisters that spread further to his face,
More informationThese precautions should be followed for 7 days after symptom onset or 24 hours after resolution of symptoms, whichever is longer.
1 of 5 11/15/2009 10:34 AM H1N1 Flu November 10, 2009 4:30 PM ET This interim guidance has been updated to replace previously posted guidance entitled Considerations Regarding Novel H1N1 Flu Virus in Obstetric
More information18 Rubella. Key information. Immunisation Handbook 2017 (2 nd edn, March 2018) 485
18 Rubella Key information Mode of transmission Incubation period Period of communicability Funded vaccine Dose, presentation, route Funded vaccine indications and schedule Pregnancy Vaccine efficacy/
More informationManagement of Viral Infection during Pregnancy
Vaccination Management of Viral Infection during Pregnancy JMAJ 45(2): 69 74, 2002 Takashi KAWANA Professor of Obstetrics and Gynecology, Teikyo University Mizonokuchi Hospital Abstract: Viral infection
More informationChickenpox Procedure. (IPC Policy Manual)
Chickenpox Procedure (IPC Policy Manual) DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Policy Approval Group Date ratified: 3 July 2018 Name of originator/author: Senior Clinical Nurse Specialist
More informationPrevention of Infections in Mothers & Infants
Helen Y. Chu, MD MPH Division of Allergy & Infectious Diseases University of Washington Prevention of Infections in Mothers & Infants June 2, 2015 Midwives Association of Washington State Conference Financial
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Registration No.: 1C 10/54 (NBC) Importer / Manufacturer: MSD (Thailand) Ltd. / Merck Sharp & Dohme Corp., West Point, Pennsylvania 19486, USA SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL
More informationSection 10.5 Varicella
Section 10.5 Varicella Chickenpox Introduction Transmission Signs and Symptoms Complications Diagnosis Treatment Infection Prevention and Control Precautions for Residents with Chickenpox Additional considerations
More informationM-M-R II Merck Sharp & Dhome
M-M-R II Merck Sharp & Dhome measles, mumps, and rubella virus vaccine live Composition (measles, mumps, and rubella virus vaccine live) is a live virus vaccine for immunization against measles (rubeola),
More informationLRI Children s Hospital. Management of chicken pox exposure in paediatrics
LRI Children s Hospital Management of chicken pox exposure in paediatrics Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team approval date: October 018 Version: V 3 Revision
More informationViral Vaccines I 5/17/04 LECTURE OUTLINE I. CASE HISTORY
Viral Vaccines I I. CASE HISTORY LECTURE OUTLINE 5/17/04 A 22-year-old Amish woman became ill with a headache, fever, and generalized muscle pain. Two days later, she developed right and then left lower
More informationPrevention of Varicella
July 12, 1996 / Vol. 45 / No. RR-11 Recommendations and Reports Prevention of Varicella Recommendations of the Advisory Committee on Immunization Practices (ACIP) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationICM VI-09 DEFINITION REFERENCES
TITLE/DESCRIPTION: MANAGEMENT OF SELECTED AIRBORNE AND DROPLET INFECTIOUS DISEASE EXPOSURES IN HEALTHCARE WORKERS INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationImportant Information About Vaccinia (Smallpox) Vaccine Please Read This Carefully
Important Information About Vaccinia (Smallpox) Vaccine Please Read This Carefully Introduction Vaccinia vaccine, previously known as smallpox vaccine, is highly effective in producing immunity to smallpox
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE Revisions as of /4/10 Zostavax should not be given concomitantly with Pneumovax 3 due to reduced immune response to Zostavax.
More informationVaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications
Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications Vaccine Prematurity 1 Altered Immunocompetence 2 (excluding human immunodefi ciency virus [HIV] infection)
More informationCongenital Cytomegalovirus (CMV)
August 2011 Congenital Cytomegalovirus (CMV) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) August 2011 August 2011 June
More informationInfection Control Manual. Table of Contents
This policy has been adopted by UNC Health Care for its use in infection control. It is provided to you as information only. I. Description Infection Control Manual Policy Name Pregnant and Post-Partum
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationSmallpox Questions and Answers: The Disease and the Vaccine
Smallpox Questions and Answers: The Disease and the Vaccine IN GENERAL What should I know about smallpox? Smallpox is an acute, contagious, and sometimes fatal disease caused by the variola virus (an orthopoxvirus),
More informationHEALTH ADVISORY: MEASLES EXPOSURES IN NEW YORK STATE
December 11, 2018 To: Health Care Providers, Hospitals, Emergency Departments, Dental Providers, and Local Health Departments From: New York State Department of Health, Bureau of Immunization HEALTH ADVISORY:
More informationHealth Care Workers (HCWs) in Ireland should have 2 doses of MMR vaccine. Two of the cases in recent outbreaks in Ireland were HCWs.
This information should be read in conjunction with Immunisation Guidelines for Ireland available at http://bit.ly/niacguidelines Summary of Product Characteristics for MMR vaccines available at www.hpra.ie
More informationSMALLPOX QUESTIONS AND ANSWERS: The Disease and the Vaccine
SMALLPOX QUESTIONS AND ANSWERS: The Disease and the Vaccine In General What should I know about smallpox? Smallpox is an acute, contagious, and sometimes fatal disease caused by the variola virus (an orthopoxvirus),
More informationShingles Procedure. (IPC Policy Manual)
Shingles Procedure (IPC Policy Manual) DOCUMENT CONTROL: Version: 1.1 Ratified by: Clinical Policy Approval Group Date ratified: 3 July 2018 Name of originator/author: Senior Clinical Nurse Specialist
More informationRecommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman
Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute
More informationWrite an account on laboratory diagnosis and prevention of chickenpox virus?
Write an account on laboratory diagnosis and prevention of chickenpox virus? The clinical presentations of varicella or zoster are so characteristic that laboratory confirmation is rarely required. Laboratory
More informationHIGH RISK IMMUNISATION
Overview HIGH RISK IMMUNISATION Dr. F Shaun Hosein Advanced Trainee, Public Health Medicine Sunshine Coast Public Health Unit Lecturer, University of Queensland Clinical Writer PHN Immunology Responses
More informationVaricella Varicella Varicella Zoster Virus Pathogenesis Clinical Features 301
Varicella Varicella is an acute infectious disease caused by varicella zoster virus (VZV). The recurrent infection (herpes zoster, also known as shingles) has been recognized since ancient times. Primary
More informationImmunization Update Richard M. Lampe M.D.
Immunization Update 2012 Richard M. Lampe M.D. Immunization Update List the Vaccines recommended for Health Care Personnel Explain why Health Care Personnel are at risk Recognize the importance of these
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF MEDICINAL PRODUCT Varilrix, 10 3.3 PFU/0.5ml, powder and solvent for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml)
More informationCenters for Disease Control and Prevention Zika Virus in Pregnancy What Midwives Need To Know
Centers for Disease Control and Prevention Zika Virus in Pregnancy What Midwives Need To Know Margaret A. Lampe, RN, MPH Pregnancy and Birth Defects Surveillance Team Zika Virus Emergency Response U.S.
More informationImmunizations Offered
Immunizations Offered Most vaccines commercially available in the United States are available at the health clinic. A partial list of available vaccines follows. For more information about specific vaccines
More informationEtiology. only one antigenic type. humans are its only known reservoir
Rubella( German meas sles ) Etiology Togaviridae family --- genus Rubivirus single-stranded RNA enveloped virus, Its core protein is surrounded by a single-layer lipoprotein envelope with spike-like projections
More informationVARICELLA. Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara
VARICELLA (Chicken pox) Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara Definition : Varicella is a common contagious disease caused
More informationDESCRIPTION OF MUMPS
New Jersey Dept. of Health and Senior Services Vaccine Preventable Disease Program Mumps Public FAQs Date: February 16, 2010 Time: 12:00 PM DESCRIPTION OF MUMPS What is mumps? Mumps is caused by a virus.
More informationVARILRIX Product Information 1(9)
VARILRIX Product Information 1(9) VARILRIX PRODUCT INFORMATION Varicella Vaccine, live attenuated DESCRIPTION VARILRIX is a lyophilised preparation of the live attenuated Oka strain of varicella-zoster
More informationChickenpox vaccine for all?
MODERN MEDICINE CPD ARTICLE NUMBER TWO: 1 point Chickenpox vaccine for all? MARK J FERSON, MB BS, MPH, MD, FRACP, FAFPHM A live attenuated varicella vaccine is now available in South Africa; it is approved
More informationINTERNATIONAL PHYSICIANS CIRCULAR. Injection M-M-R II. (MEASLES, MUMPS, and RUBELLA VIRUS VACCINE LIVE) WORLDWIDE PRODUCT LABELING MRL
SG-IPC-V205C-I-122014 INTERNATIONAL PHYSICIANS CIRCULAR Injection M-M-R II (MEASLES, MUMPS, and RUBELLA VIRUS VACCINE LIVE) WORLDWIDE PRODUCT LABELING MRL M-M-R II (Measles, Mumps, and Rubella Virus Vaccine
More informationHuman Zoster Immunoglobulin, solution for intramuscular injection.
Product Information Zoster Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Zoster Immunoglobulin, solution for intramuscular injection. DESCRIPTION Zoster Immunoglobulin-VF is a sterile, preservative-free
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationCOFM Immunization Policy
COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy This policy applies to all undergraduate medical students attending an Ontario medical
More information9/11/2018. Measles. Measles, Mumps, and Rubella. Measles Complications. Paramyxovirus Nasopharynx is primary site of infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Measles, Mumps, and Rubella September 2018 Chapters 13, 15 and 20 Photographs and images included in
More informationMeasles 2015: What We Need to Know
Faculty Measles 2015: What We Need to Know Karen Landers, MD, FAAP Assistant State Health Officer Tuberculosis Control and Immunization Alabama Department of Public Health Produced by the Alabama Department
More informationImmunizations for Health Care Workers
Immunizations for Health Care Workers Tanisha Taylor, MD, MPH Senior Medical Director Barnabas Health Corporate Care Tanisha Taylor MD, MPH Senior Medical Director Barnabas Health Corporate Care CDC Immunizations
More informationVaccination to protect against shingles
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2018 and contraindications and precautions Revised July 2018 NES and HPS accept
More informationCOFM Immunization Policy 2016
COFM Immunization Policy 2016 Council of Ontario Faculties of Medicine June 2016 COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy 2016
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationProtecting Infants and Children from Pertussis and Influenza
September 23, 2016 Paulomi Shah, DO, FAAP Pediatrician, Medical Director Children s Medical Services, Sonoma County Alan Shotkin, MD, FAAP Neonatologist, Medical Director Santa Rosa Memorial Hospital Protecting
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationH1N1-A (Swine flu) and Seasonal Influenza
H1N1-A (Swine flu) and Seasonal Influenza Influenza, commonly known as the flu, is a contagious viral disease that typically occurs in the winter months and causes cough, fever, sore throat, headache,
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 02/2017 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VARIVAX safely and effectively. See full prescribing information for VARIVAX. VARIVAX Varicella Virus
More informationVaccine Preventable Diseases and healthcare workers
Vaccine Preventable Diseases and healthcare workers Expected learning outcomes At the end of this activity, you will: understand your responsibility to manage increased risks associated with vaccine preventable
More informationHealthcare Personnel Immunization Recommendations
Healthcare Personnel Immunization Recommendations Kathleen Harriman, PhD, MPH, RN California Department of Public Health Immunization Branch Vaccine Preventable Disease Epidemiology Section kathleen.harriman@cdph.ca.gov
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More informationPersistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults
MAJOR ARTICLE Persistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults Krow Ampofo, 1 Lisa Saiman, 1,2 Philip LaRussa, 1 Sharon Steinberg, 1 Paula Annunziato, 1 and Anne Gershon 1
More informationVaccines and Adults: Our Collective Challenge Webinar
Vaccines and Adults: Our Collective Challenge Webinar Questions 1. What documentation would a pediatrician need to immunize adult parents to avoid some risk since they are non-patients of the practice
More informationContraindications to breast feeding. Dr. Ahmed Isam
Contraindications to breast feeding Dr. Ahmed Isam When should a mother avoid breastfeeding? Health professionals agree that human milk provides the most complete form of nutrition for infants, including
More informationWashtenaw County Community Mental Health HEALTH CARE PERSONNEL (HCP) VACCINES (RECOMMENDED EMPLOYEE IMMUNIZATIONS)
Washtenaw County Community Mental Health HEALTH CARE PERSONNEL (HCP) VACCINES (RECOMMENDED EMPLOYEE IMMUNIZATIONS) PURPOSE To reduce the risk of exposure of Washtenaw County Community Mental Health (CMH)
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017
Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationChickenpox and Shingles
Chickenpox and Shingles (Chickenpox is also known as varicella. Shingles is also known as herpes zoster.) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per NJAC 8:57, health care providers and administrators
More informationSerum Institute of India Ltd. The Nasal-Spray Flu Vaccine (Live Attenuated Influenza Vaccine [LAIV])
Nasovac The Nasal-Spray Flu Vaccine (Live Attenuated Influenza Vaccine [LAIV]) Questions & Answers Who can be vaccinated with the nasal-spray flu vaccine LAIV (Nasovac )? LAIV (Nasovac ) is approved for
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationBio-Rad Laboratories. The Best Protection Whoever You Are. Congenital and Pediatric Disease Testing
Bio-Rad Laboratories I N F E C T I O U S D I S E A S E T E S T I N G The Best Protection Whoever You Are Congenital and Pediatric Disease Testing Bio-Rad Laboratories I N F E C T I O U S D I S E A S E
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationAlphaherpesvirinae. Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV)
Alphaherpesvirinae Simplexvirus (HHV1&2/ HSV1&2) Varicellovirus (HHV3/VZV) HERPES SIMPLEX VIRUS First human herpesvirus discovered (1922) Two serotypes recognised HSV-1 & HSV-2 (1962) HSV polymorphism
More informationSeasonal Influenza in Pregnancy and Puerperium Guideline (GL1086)
Seasonal Influenza in Pregnancy and Puerperium Guideline (GL1086) Approval Approval Group Job Title, Chair of Committee Date Maternity & Children s Services Clinical Governance Committee Chair, Maternity
More informationCHANGCHUN CHANGSHENG LIFE SCIENCES LTD. Address: No.1615Yueda Road, Changchun, China Postcode: Summary of Product Characteristics
Summary of Product Characteristics 1. Name of the medicinal product Generic name: Varicella Vaccine (live) I.P, Freeze-dried 2. Qualitative and quantitative composition The composition of the product is
More informationMEASLES, MUMPS, RUBELLA (MMR)
MEASLES, MUMPS, RUBELLA (MMR) WHAT YOU NEED TO KNOW ARE YOU SURE YOU USE THE RIGHT MEASURES TO PROTECT YOURSELF AGAINST MEASLES, MUMPS OR RUBELLA? GET INFORMED! GET VACCINATED! GET PROTECTED! MMR VACCINE
More informationHepatitis B Immune Globulin Biological Page
Hepatitis B Immune Globulin Biological Page Section 7: Biological Product Information Standard #: 07.233 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationLecture-7- Hazem Al-Khafaji 2016
TOXOPLASMOSIS Lecture-7- Hazem Al-Khafaji 2016 TOXOPLASMOSIS It is a disease caused by Toxoplasma gondii which is a protozoan parasite that is infects a variety of mammals and birds throughout the world.
More informationJoint Commission 2010 Guidelines: Influenza Vaccinations for Health-Care Workers
Joint Commission 2010 Guidelines: Influenza Vaccinations for Health-Care Workers Axion Health, Inc. 7403 Church Ranch Blvd Suite 110 Westminster, CO 80503 www.axionhealth.com Employee health and employee
More informationFACT SHEET FOR ADDITIONAL INFORMATION CONTACT
FACT SHEET FOR ADDITIONAL INFORMATION CONTACT Caroline Calderone Baisley, MPH, RS Michael S. Long, MS Director of Health Director of Environmental Services Tel. 203-622-7836 Tel: 203-622-7838 SMALLPOX:
More informationA Call To Arms: The Basics for Select Vaccines
Page 1 A Call To Arms: The Basics for Select Vaccines A Call To Arms: The Basics for Select Vaccines Wendy Rosenthal, Pharm.D. A Call To Arms: The Basics for Select Vaccines Vaccine Science Basics of Immunity
More informationNew Jersey Department of Health Vaccine Preventable Disease Program Mumps Public Frequently Asked Questions. Date: September 9, 2013
New Jersey Department of Health Vaccine Preventable Disease Program Mumps Public Frequently Asked Questions Date: September 9, 2013 DESCRIPTION OF MUMPS What is mumps? Mumps is a contagious disease that
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 To provide guidelines for administering immunizations. PURPOSE POLICY Immunizations are to be administered to all patients in accordance with the North Carolina Immunization Regulations and
More information9/12/2018. Zoster. Herpes Zoster (Shingles) Complications of Herpes Zoster
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Zoster September 2018 Chapter 22 Photographs and images included in this presentation are licensed solely
More informationDISCLOSURES. I have no actual or potential conflicts of interest in this presentation.
OVERVIEW ON MEASLES Oneka B. Marriott, DO, MPH, FAAP, FACOP Assistant Professor of Pediatrics and Public Health Nova Southeastern University College of Osteopathic Medicine Presentation to FSACOFP Annual
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Varicella Zoster Virus (VZV)
Southern Derbyshire Shared Care Pathology Guidelines Varicella Zoster Virus (VZV) Purpose of guideline This guideline provides information about the definition of significant exposure to VZV and management
More information